AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca u.S. gross product sales before rebates, chargebacks & discounts ($M) ($M)
Form 20-F Note 2 — U.S. Gross-to-Net Sales Rebates, Chargebacks & Returns
Latest, FY2025
47,385
Period ended Dec 31, 2025
Change on a year earlier
+16.6%
40,641 in FY2024
History
3 years
Since FY2023
Sources
1
Form 20-F FY2025 Annual Report
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. gross product sales before rebates, chargebacks & discounts ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47,385 | +16.6% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 40,641 | +11.1% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 36,568 | – | Form 20-F FY2025 Annual Report ↗ |
Breakdown
What makes up u.s. gross product sales before rebates, chargebacks & discounts ($m)
Cite this data
StockData. (2026). AstraZeneca U.S. gross product sales before rebates, chargebacks & discounts ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/us_gtn_gross
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.